

Special Issue

Targeted Therapies for Cancer

Message from the Guest Editors

Over the last two decades, the new insights into the biology and the signaling pathways of tumor cells and cells of the tumor microenvironment involved in tumor growth and spread, led to the development of the so called targeted therapies. Their cornerstone is represented by the identification of specific molecular and cellular targets, endowed with a pivotal role in cell growth and survival, useful for cancer diagnosis and actionable in anti-tumor strategies. To date, several targeted therapies were developed and many of them have been recently approved by the Food and Drug Administration for treating different types of cancer. At present, the most commonly investigated targeted therapies are based on the use of small molecules inhibitors, monoclonal antibodies and immunotoxins. In this context, also nano-delivery systems can be easily included among the cell targeted therapies. Indeed, they exploit the presence of tumor-associated antigens on the cell surface of tumor cells and cells of the tumor microenvironment, to specifically deliver their payload (e.g. chemotherapeutics, small molecule inhibitors, siRNA) to diseased tissues, while reducing healthy organs uptake.

Guest Editors

Dr. Chiara Brignole

Area Aggregazione Laboratori Ricerca, U.O.S.D. Laboratorio Terapie Sperimentali in Oncologia, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy

Dr. Fabio Pastorino

Area Aggregazione Laboratori Ricerca, U.O.S.D. Laboratorio Terapie Sperimentali in Oncologia, IRCCS Istituto Giannina Gaslini, Genoa, Italy

Deadline for manuscript submissions

closed (15 February 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/78914

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).